Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Melanoma 387Skin Neoplasms 91Carcinoma, Non-Small-Cell Lung 78Breast Neoplasms 56Neoplasms 55Colorectal Neoplasms 52Lung Neoplasms 51Neoplasm Metastasis 46Ovarian Neoplasms 44Lymphoma, T-Cell, Cutaneous 44Carcinoma, Renal Cell 43Squamous Cell Carcinoma of Head and Neck 42Uveal Melanoma 39Pancreatic Neoplasms 37Sarcoma 36Carcinoma, Basal Cell 36Head and Neck Neoplasms 33Uterine Cervical Neoplasms 32Prostatic Neoplasms 32Stomach Neoplasms 30Carcinoma, Hepatocellular 30Endometrial Neoplasms 29Carcinoma, Merkel Cell 29Urinary Bladder Neoplasms 28Kidney Neoplasms 26Triple Negative Breast Neoplasms 24Carcinoma, Squamous Cell 23Esophageal Neoplasms 22Lymphoma 21Mycosis Fungoides 19

Interventions

Paroxetine 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lethal Congenital Contracture Syndrome 2 × Dermatologic × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡